Delimotecan

N/A

Report date: 2023/09/25 16:01:16
NME

Base Information

Drug NameDelimotecan
Drug Alias Name德立替康delimotecanum德莫替康T-0128MEN-4901
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A